Long-term hormone monotherapy has been the standard of care for patients with PCa for more than 60 years. The purpose of this study was to compare the efficacy of 2 new treatment standards using a patient subset of the STAMPEDE trial.
The phase 3 OAK trial demonstrated that previously treated patients with advanced NSCLC experienced prolonged OS with atezolizumab compared to docetaxel regardless of PD-L1 status.
The relative effects of FLOT were demonstrable in all subgroups, and was pronounced numerically in patients with Barrett tumors, small tumors T1/2, nodal negative tumors, and Siewert type 1 esophageal tumors.
Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.
Although guidelines advocate follow-ups consisting of clinic visits and CT-scans, there is a lack of robust data supporting these recommendations.
Patients with untreated FL were randomly assigned to receive cyclophosphamide, vincristine, and prednisone (CVP) plus rituximab (R) or GP2013 for 8 cycles followed by 2 years of monotherapy maintenance in patients who responded to treatment.
Although there was less toxicity, neoadjuvant letrozole plus palbociclib had similar response and BCS rates when compared with chemotherapy.
This trial sought to determine if the letrozole and taselisib combination was effective in early-stage breast cancer.
The non-inferiority of the sorafenib (So) and pazopanib (Pa) sequence was not demonstrated compared to pazopanib-sorafenib in patients with metastatic renal cell carcinoma (mRCC).
Though a longer overall survival was observed in patients who received pertuzumab plus trastuzumab and chemotherapy, it was not statistically significant.
